NasdaqGS - Nasdaq Real Time Price
USD
Gilead Sciences, Inc. (GILD)
131.65
+0.81
(+0.62%)
At close: May 1 at 4:00:01 PM EDT
131.83
+0.18
(+0.14%)
After hours: May 1 at 7:55:59 PM EDT
Trade GILD on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreLoading chart for GILD
- Previous Close
130.84 - Open
130.00 - Bid 125.69 x 100
- Ask 138.10 x 100
- Day's Range
129.01 - 132.36 - 52 Week Range
95.30 - 157.29 - Volume
5,516,823 - Avg. Volume
6,463,265 - Market Cap (intraday)
163.404B - Beta (5Y Monthly) 0.40
- PE Ratio (TTM)
19.42 - EPS (TTM)
6.78 - Earnings Date May 7, 2026
- Forward Dividend & Yield 3.28 (2.49%)
- Ex-Dividend Date Mar 13, 2026
- 1y Target Est
158.36
Recent News: GILD
View More
Performance Overview: GILD
Trailing total returns as of 5/1/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
GILD
7.87%
S&P 500 (^GSPC)
5.62%
1-Year Return
GILD
30.90%
S&P 500 (^GSPC)
29.01%
3-Year Return
GILD
79.00%
S&P 500 (^GSPC)
73.47%
5-Year Return
GILD
149.90%
S&P 500 (^GSPC)
72.92%
Earnings Trends: GILD
View MoreAnalyst Insights: GILD
View MoreStatistics: GILD
View MoreValuation Measures
As of 5/1/2026
-
Market Cap
163.40B
-
Enterprise Value
178.73B
-
Trailing P/E
19.42
-
Forward P/E
15.06
-
PEG Ratio (5yr expected)
0.37
-
Price/Sales (ttm)
5.61
-
Price/Book (mrq)
7.20
-
Enterprise Value/Revenue
6.07
-
Enterprise Value/EBITDA
13.16
Financial Highlights
Profitability and Income Statement
-
Profit Margin
28.90%
-
Return on Assets (ttm)
12.52%
-
Return on Equity (ttm)
40.65%
-
Revenue (ttm)
29.44B
-
Net Income Avi to Common (ttm)
8.51B
-
Diluted EPS (ttm)
6.78
Balance Sheet and Cash Flow
-
Total Cash (mrq)
9.61B
-
Total Debt/Equity (mrq)
112.92%
-
Levered Free Cash Flow (ttm)
7.54B
Compare To: GILD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Company Insights: GILD
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports: GILD
View More-
Gilead: Arcellx Acquisition Shows Conviction in Anito-Cel's Potential Versus J&J's Carvykti
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
RatingPrice Target -
The Argus High-Yield Model Portfolio
Value stocks -- a market segment that includes high-yield stocks -- outperformed growth stocks in 2022. In 2025, value stocks and growth stocks had similar returns, with growth advancing 13.8% and value returning 13.6%. That's a recent rarity, as for the past decade-plus, the performance record has favored growth. But in 2022, the rollout of COVID-19 vaccines gave a lift to some of the cyclical companies (energy and regional banks), and value stocks outpaced growth stocks that year. While growth stocks led for a few years after that, value stocks are back in the picture as investors rotate out of higher-priced AI growth stocks in search of more reasonable valuations. Value stocks tend to be more resilient in times of market uncertainty and higher volatility as they are less likely to overreact to economic news. In any event, the value sector is the place to achieve income.
-
Gilead: Arcellx Acquisition Shows Conviction in Anito-Cel's Potential Versus J&J's Carvykti
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
RatingPrice Target -
Raising target price to $165
Gilead Sciences is a biopharmaceutical company that researches, develops, and sells therapies for treating HIV, hepatitis B, hepatitis C, and certain cancers. In October 2020, Gilead's Veklury (remdesivir) became the first approved treatment for COVID-19 in the U.S. Founded in 1987, the company is based in Foster City, California. It has operations in more than 40 countries and more than 18,000 employees.
RatingPrice Target
